Oberadilol
Изглед
Nazivi | |
---|---|
Preferisani IUPAC naziv
4-hloro-2-[2-hidroksi-3-[[2-metil-1-[4-(4-metil-6-oksi-4,5-dihidro-1H-piridazin-3-il)anilino]propan-2-il]amino]propoksi]benzonitril | |
Drugi nazivi
114856-44-9
7ZNX9ET039 DTXSID2048745 OBERADILOL MONOETHYL MALEATE UNII-7ZNX9ET039 SCHEMBL8813275 CHEMBL2105183 DTXCID9028671 Tox21_113202 NCGC00249416-01 CAS-114856-44-9 L001360 Q27269078 | |
Identifikacija | |
3D model (Jmol)
|
|
UNII | |
| |
Svojstva | |
C25H30ClN5O3 | |
Molarna masa | 484,00 g·mol−1 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
Reference infokutije | |
Oberadilol je agonist beta adrenergičkog receptora.[3]
Reference
[уреди | уреди извор]- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Mark J. Henderson; Kathleen A. Trychta; Shyh-Ming Yang; Yun Wang; Anton Simeonov; Brandon K. Harvey (2021). „A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome”. Cell Reports. doi:10.1016/j.celrep.2021.109040.